Vetoquinol SA (EPA:VETO)

Market Cap	866.14M
Revenue (ttm)	537.47M
Net Income (ttm)	47.14M
Shares Out	11.83M
EPS (ttm)	3.98
PE Ratio	18.37
Forward PE	15.08
Dividend	0.85 (1.17%)
Ex-Dividend Date	Jun 4, 2024

Volume	4,703
Average Volume	8,711
Open	73.00
Previous Close	72.90
Day's Range	72.50 - 73.40
52-Week Range	63.60 - 106.20
Beta	0.90
RSI	53.25
Earnings Date	Mar 20, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,440
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2023, Vetoquinol's revenue was 529.27 million, a decrease of -1.95% compared to the previous year's 539.78 million. Earnings were 55.56 million, an increase of 15.76%.